Nebivolol and Telmisartan Tablet

NEBROOT-H 5

Nebivolol 5 mg and Telmisartan 40 mg Tablets

Division: DIABGLYM

Composition

Each tablet contains:

Nebivolol IP — 5 mg

Telmisartan IP — 40 mg

Excipients — q.s.

Colour: Approved colour used

Dosage form: Oral tablet

Product Description

NEBROOT-H 5 is a scientifically balanced antihypertensive combination of Nebivolol 5 mg and Telmisartan 40 mg, formulated for the effective management of hypertension and long-term cardiovascular protection. This combination provides dual blood pressure control by combining the highly selective beta-1 blocking and nitric oxide-mediated vasodilatory effects of Nebivolol with the renin-angiotensin system blockade of Telmisartan, resulting in superior antihypertensive efficacy and enhanced cardiovascular and renal protection.

Nebivolol is a third-generation beta-1 selective blocker with additional nitric oxide-mediated vasodilatory properties that helps reduce heart rate, myocardial oxygen demand, and vascular resistance while improving endothelial function. Telmisartan is a long-acting angiotensin II receptor blocker (ARB) that promotes vasodilation, reduces peripheral vascular resistance, provides cardiovascular and renal protection, and has favorable metabolic effects.

NEBROOT-H 5 is particularly beneficial in patients with hypertension associated with tachycardia, diabetes, chronic kidney disease, coronary artery disease, metabolic syndrome, obesity, and patients requiring combination antihypertensive therapy with heart rate control.

Technical Knowledge of Nebivolol and Telmisartan

Nebivolol selectively blocks beta-1 adrenergic receptors in the heart and stimulates endothelial nitric oxide release, producing vasodilation, reduced heart rate, decreased myocardial contractility, improved endothelial function, enhanced vascular compliance, and reduced peripheral vascular resistance.

Telmisartan selectively blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction, aldosterone secretion, sympathetic activation, and vascular remodeling. Telmisartan also exhibits partial PPAR-gamma agonistic activity, which may contribute to favorable metabolic effects in patients with insulin resistance and metabolic syndrome.

The combination of Nebivolol and Telmisartan provides complementary antihypertensive mechanisms with additional cardiovascular, renal, and endothelial protective benefits.

Mechanism of Action

Nebivolol selectively blocks beta-1 receptors, reduces heart rate and myocardial contractility, stimulates nitric oxide-mediated vasodilation, improves endothelial function, decreases peripheral vascular resistance, and reduces myocardial oxygen demand.

Telmisartan blocks AT1 receptors, promotes vasodilation, reduces peripheral vascular resistance, decreases aldosterone secretion, improves vascular function, and protects cardiovascular and renal tissues.

Key Benefits

Effective reduction of systolic and diastolic blood pressure

Dual antihypertensive mechanism

Provides sustained 24-hour blood pressure control

Reduces heart rate and myocardial workload

Supports cardiovascular and renal protection

Improves endothelial function

Favorable metabolic profile

Convenient once-daily dosing

Suitable for long-term hypertension management under medical supervision

Clinical Applications

NEBROOT-H 5 is commonly prescribed for essential hypertension, hypertension with tachycardia, hypertension with diabetes mellitus, hypertension with chronic kidney disease, hypertension with coronary artery disease, metabolic syndrome, obesity-associated hypertension, and long-term cardiovascular risk reduction.

Facts About Nebivolol and Telmisartan

Nebivolol is a modern beta-blocker with nitric oxide-mediated vasodilatory activity and excellent metabolic and endothelial profiles. Telmisartan is a long-acting ARB with proven cardiovascular and renal protective benefits and favorable effects on insulin sensitivity. The combination is particularly useful in hypertensive patients requiring both blood pressure reduction and heart rate control with comprehensive cardiovascular protection.

Key Facts

Beta-blocker and ARB combination therapy

Nebivolol 5 mg for heart rate control and endothelial support

Telmisartan 40 mg for vascular and renal protection

Provides sustained 24-hour antihypertensive action

Effective in hypertension with diabetes and chronic kidney disease

Evidence-based cardiovascular combination therapy

Quality-assured pharmaceutical formulation

PCD Pharma Franchise Opportunity

NEBROOT-H 5 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, coronary artery disease, chronic kidney disease, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this combination.

Why Choose NEBROOT-H 5 for PCD Pharma Franchise?

High prescription potential

Strong physician and cardiologist acceptance

Attractive monopoly franchise opportunity

Competitive pricing

Promotional support available

Visual aids and marketing inputs

Consistent product quality

Excellent repeat business potential

Third Party Manufacturing

Chemsroot Pharmaceutical offers Third Party Manufacturing of Nebivolol 5 mg and Telmisartan 40 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses.

Our Third Party Manufacturing Services Include

Private label manufacturing

Contract manufacturing

Custom brand manufacturing

Loan license manufacturing

DCGI-compliant production

GMP-certified manufacturing

Batch manufacturing documentation

Product registration support

Customized packaging and artwork

Monopoly franchise packaging

Bulk manufacturing capability

Manufacturing Features

Pharmaceutical-grade raw materials

IP/BP/USP quality standards

In-process quality control

Finished product testing

Stability-oriented formulation

Moisture-controlled tablet manufacturing

Blister and Alu-Alu packaging options

NEBROOT-H 5 from DIABGLYM combines effective blood pressure control, heart rate management, comprehensive cardiovascular and renal protection, evidence-based combination therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, nephrologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Nebivolol and Telmisartan formulation.